Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.


OBJECTIVE To determine overall survival (OS), progression-free interval (PFI), and toxicity in patients with advanced stage or recurrent endometrial cancer (EMCA) treated with combination paclitaxel, carboplatin and megestrol acetate. STUDY DESIGN Patients with stage III/IV or recurrent EMCA were enrolled between October 2004 and April 2008 and received… (More)


  • Presentations referencing similar topics